/News/Suppliers — Danish biosolutions company Novonesis and healthcare company Novo Nordisk have entered a research partnership to explore the role of the gut microbiome in the maintenance of metabolic health. The global firms, each leaders in their fields, will work to develop synbiotic food biotic solutions to support users’ blood glucose and cholesterol levels. As well as investigating how the gut microbiome may be used to monitor and predict metabolic and overall health trajectories, the companies will explore novel biomarkers with the aim of measuring the effectiveness of gut microbiome solutions. “Cardiometabolic health is deeply influenced by the microbiome, which makes it a central focus for new innovations in microbiome biotic solutions,” Dr. Baker said. “Our new partnership will open the door to new biosolutions, such as scientifically backed dietary supplements that support metabolic health and overall well-being.”Weight management expertiseNovo Nordisk is a global firm with products marketed in around 170 countries.